Back to top
more

Boston Scientific (BSX)

(Delayed Data from NYSE)

$87.59 USD

87.59
5,119,705

-1.18 (-1.33%)

Updated Nov 14, 2024 04:00 PM ET

After-Market: $87.59 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical - Products

Zacks News

Boston Scientific (BSX) Q1 Earnings Beat, Organic Sales Up

Boston Scientific (BSX) registers strong sequential improvement in overall financial performance in Q1.

Boston Scientific (BSX) Q1 Earnings and Revenues Surpass Estimates

Boston Scientific (BSX) delivered earnings and revenue surprises of 23.33% and 5.30%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

Medical Product Stocks' Earnings on Apr 28: BSX, ALGN & More

The sector's Q1 results are likely to reflect solid earnings and revenue growth on strong base business recovery.

Why Boston Scientific (BSX) Might Surprise This Earnings Season

Boston Scientific (BSX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Boston Scientific's (BSX) Watchman US Sale to Aid Q1 Earnings

Within Boston Scientific's (BSX) coronary therapies, drug-eluting stents sale continue to be a challenge from a pricing standpoint in Q1.

The Zacks Analyst Blog Highlights: NIKE, Applied Materials, Square, Boston Scientific and Petrobras

The Zacks Analyst Blog Highlights: NIKE, Applied Materials, Square, Boston Scientific and Petrobras

Sheraz Mian headshot

Top Research Reports for NIKE, Applied Materials & Square

Today's Research Daily features new research reports on 16 major stocks, including NIKE (NKE), Applied Materials (AMAT), and Square (SQ).

Boston Scientific (BSX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Boston Scientific (BSX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Hold on to Medtronic (MDT) Stock for Now

Investors continue to be optimistic about Medtronic (MDT) on its slew of product launches and regulatory approvals.

Late-Breaking Data Supports Boston Scientific's (BSX) TheraSphere

Boston Scientific's (BSX) TheraSphere is expected to be used as a safe and effective treatment option for numerous HCC patients worldwide on the back of positive trial results.

DaVita (DVA) Partners With Fresenius, Boost Home Dialysis Care

DaVita's (DVA) recent collaboration will help patients benefit from the portability, dependability and flexibility of NxStage home machines, designed to be easy to use.

Boston Scientific (BSX) Hurt by Product Recall, Currency Woes

Boston Scientific (BSX) currently expects its 2021 organic revenues to include a headwind of $62 million from 2020 LOTUS Edge sales.

Boston Scientific's (BSX) TheraSphere Approved by FDA for HCC

Boston Scientific's (BSX) TheraSphere therapy to be made accessible to more patients following the FDA's clearance.

Boston Scientific (BSX) Down 2.1% Since Last Earnings Report: Can It Rebound?

Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Boston Scientific (BSX) Buys Lumenis to Expand in Urology

The transaction is expected to remain immaterial to Boston Scientific's (BSX) 2021 adjusted earnings per share.

Here's Why You Should Hold on to Medtronic (MDT) Stock for Now

Investors continue to be optimistic about Medtronic (MDT) on slew of product launches and regulatory approvals.

Urmimala Biswas headshot

4 Medical Products Stocks Set to Beat This Earnings Season

Rebound in sales volumes and rise in COVID-19 support products sales make us optimistic about MDT, MASI, XRAY and COO's results.

Boston Scientific (BSX) Hurt by Product Recall, Conversion

Barring MedSurg, organic revenues at each of Boston Scientific (BSX) core segments and geographies are down in Q4 but the magnitude of this decline is lower than Q3.

Boston Scientific (BSX) Q4 Earnings Miss, Margins Decline

Apart from a drop in Q4 earnings and revenues drop year over year, Boston Scientific (BSX) also registers strong sequential decline in overall financial performance.

Boston Scientific (BSX) Q4 Earnings and Revenues Lag Estimates

Boston Scientific (BSX) delivered earnings and revenue surprises of -25.81% and -0.02%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Radhika Pujara headshot

Skyworks (SWKS) & 3 Other Suppliers to Tap Uptick in iPhone Sales

Shares of Skyworks (SWKS) are skyrocketing post upbeat guidance and impressive Q1 performance driven by uptick in Apple's (AAPL) iPhone 12 sales. This positions other suppliers, including QRVO, JBL & SYNA, well to gain from the projected increase in iPhone 12 demand.

Skyworks' (SWKS) Q1 Earnings Top Estimates, Stock Up on Q2 View

Skyworks' (SWKS) fiscal first-quarter results gain from rapid 5G deployment and strength in overall broad markets.

Boston Scientific (BSX) LOTUS Edge Recall to Mar Q4 Earnings

Per Boston Scientific's (BSX) October update, it has started to see strong region-wise recovery.

Boston Scientific's (BSX) DBS System Gets FDA's Clearance

The latest FDA approval of Boston Scientific's (BSX) fourth-generation Vercise Genus DBS System is aimed at improving patients' quality of life.

Boston Scientific (BSX) Enhances Core Business With Buyout

Boston Scientific's (BSX) acquisition of Preventice solutions enables the former to expand rhythm management diagnostics portfolio and abilities.